Kancera AB (publ) (KAN.ST)
Kancera AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Solna, SE. The stock last traded at $0.30, up 0.00% on the session, giving a market capitalisation of $36.1M. Its beta of 0.92 implies it has historically moved less than the broad market.
Kancera AB (publ), a biopharmaceutical firm founded in Solna, Sweden, in 2010, specializes in the development of new treatments for inflammatory disorders and various types of cancer, operating both domestically and internationally. The company's pipeline includes several small molecule drug candidates. KAND567 is presently in a Phase IIa clinical trial, assessing its effectiveness against inflammatory heart disease occurring after a heart attack. Additionally, KAND145 is undergoing a Phase I study with healthy volunteers to establish optimal dosing for cancer therapy, alongside a Phase IIa study specifically targeting ovarian cancer. Kancera's research efforts also encompass HDAC inhibitors for managing nerve inflammation and pain, as well as ROR1 inhibitors for addressing solid tumors and blood-related cancers.
Kancera AB (publ) is most often compared with the following Healthcare names: